About
Colin Freund is chair and former founding CEO of Athernal Bio. With 18 years of experience in private and public biotechnology, he has led multinational teams across company leadership, strategic planning, business development, and M&A transactions exceeding $500 million, while managing regulatory strategy, commercial development, and fundraising activities in the US, Europe, and Asia.
Experience
- Athernal BioChair (former founding CEO)current2024 β presentCambridge
- mothers2mothersChair of the Boardcurrent2019 β present
- Swarm OncologyBoard Membercurrent2024 β presentLondon Area, United Kingdom
- Modra PharmaceuticalsBoard Membercurrent2024 β present
- Modra PharmaceuticalsCEO2017 β 2023Amsterdam Area, Netherlands
- TurbineBoard Member2024 β 2025
- Delin VenturesPartner2023 β 2025London, England, United Kingdom
- IMMvention Therapeutix, Inc.Board Member2024 β 2025
- Citryll B.V.Board Member2022 β 2024Oss, North Brabant, Netherlands
- QUE Oncology, Inc.Advisor2017
- QUE Oncology, Inc.Chief Executive Officer2015 β 2017Greater New York City Area | Atlanta, GA | Brisbane, Australia
- Transgene SAChief Business Officer 11/13-06/15, Senior Business Advisor (07/15-12/15)2013 β 2015Cambridge, MA | Strasbourg, France
- Agennix AGChief Business Officer2009 β 2013Princeton, NJ
- GPC Biotech AGSenior Vice President Business Development & Corporate Strategy2007 β 2009Princeton, NJ
- GPC Biotech AGVice-President, Business Development2003 β 2007Princeton, NJ
- GPC Biotech AGSenior Director, Business Development2002 β 2003Munich, Germany | Waltham, MA
- Doubletwist Inc.Vice President, Business Development1999 β 2001Oakland, CA
- the Boston Consulting GroupProject Leader1992 β 1999London, England | San Francisco, CA
Education
- Stanford University Graduate School of BusinessMasters, Business Administration
- University of CambridgeBA, Economics & Management Studies
Skills & more
Social EntrepreneurshipOrganizational EffectivenessStakeholder ManagementStrategic PartnershipsLeadership DevelopmentNon-profit ManagementStrategic ThinkingBoard DevelopmentDrug DevelopmentStrategic NegotiationsClinical TrialsStrategic Planning
+12 more
Strategic LeadershipPresentationsConsultingPartner Relationship ManagementContract NegotiationStakeholder EngagementExecutive LeadershipChange ManagementCommunicationStrategyLeadershipNegotiationLanguages English Β· French Β· German
From Colin's professional profile.
Same school
Also attended Stanford University Graduate School of Business1,150
Roelof BothaAdvisor & former Steward at Sequoia Capital; SpaceX board memberPeter FentonGeneral Partner at BenchmarkSteve JurvetsonCo-founder of Future VenturesDavid SzeAdvisory Partner at GreylockKatherine BoyleGeneral Partner at Andreessen Horowitz (American Dynamism)Hunter WalkCo-founder & Partner at Homebrew
+ 1,144 more
Also attended University of Cambridge621
Niko BonatsosInvestment Team at General CatalystGeorgia StevensonInvestor at Index VenturesHannah SealInvestor at Index VenturesAnthony PhilippakisInvestor at GV (Google Ventures)Erik NordlanderInvestor at GV (Google Ventures)Nic LowdenInvestor at Moonfire Ventures
.png)
+ 615 more
Shared employers
Also worked at Swarm Oncology4
Also worked at Turbine6
Also worked at the Boston Consulting Group681
David SzeAdvisory Partner at GreylockDave MunichielloInvestor at GV (Google Ventures)Massimo PrelzInvestor at DN CapitalRasmus AreskougInvestor at DN CapitalRiccardo MontiOperating Advisor at P101 VenturesAntonio TurroniOperating Advisor at P101 Ventures
+ 675 more
Colleagues at Delin Ventures
Alan Barge
Venture Partner at Delin Ventures
Carol Lynch
Advisor at Delin Ventures
Caroline Haegeman
Associate at Delin Ventures
Christopher Spray
Advisor at Delin Ventures
Colin Sims
Partner at Delin Ventures
Igor Linshits
Founder at Delin Ventures
Iskender Dirik
Partner at Delin Ventures
Δ°skender Dirik
Partner at Delin Ventures